CALGARY, Feb. 8, 2012 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the
"Company") (TSX:RVX) is pleased to announce that Donald McCaffrey,
President & Chief Executive Officer of Resverlogix will be presenting
at The 14th Annual BIO CEO & Investor Conference on February 13, 2012 at 1:30 PM
(EST) at the Waldorf Astoria, New York City.

Resverlogix will also post the Webcast link to the Events section of
their website at: http://www.resverlogix.com/media/events. The archived replay will be available for a period of 45 days
following the live event.

About Resverlogix

Resverlogix is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets
with significant unmet medical needs. These vital therapies are focused
on addressing the burden of Atherosclerosis and many other important
diseases including Acute Coronary Syndrome, Alzheimer's disease,
Peripheral Artery Disease and Autoimmune diseases. The NexVas Plaque
Regression program is the Company's primary focus which is to develop
novel small molecules that enhance ApoA-I production and thereby raise
high density lipoprotein (HDL) for the treatment of Atherosclerosis.
Lead drug RVX-208 is currently in two Phase 2b Clinical Trials led by
the Cleveland Clinic. Resverlogix's common shares trade on the Toronto
Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as
defined under applicable Canadian securities legislation that are not
based on historical fact, including without limitation statements
containing the words "believes", "anticipates", "plans", "intends",
"will", "should", "expects", "continue", "estimate", "forecasts" and
other similar expressions. Our actual results, events or developments
could be materially different from those expressed or implied by these
forward-looking statements. We can give no assurance that any of the
events or expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous assumptions and
risks including but not limited to those assumptions and risk factors
discussed in the Company's Annual Information Form and MD&A for the
interim period ended October 31, 2011 which are incorporated herein by
reference and other documents we file from time to time with securities
authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of the
date hereof. The Company disclaims any intention and has no obligation
or responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.